PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies

Abstract excerpt

The introduction of poly (ADP-ribose) polymerase inhibitors (PARPi) into the management of ovarian cancer has transformed the treatment landscape for patients affected by this malignancy. However, as the use of PARPi expands into both frontline maintenance and recurrence settings, the emergence of drug resistance has become a significant clinical challenge in the treatment of these patients. Although...

Topics

Join the communities discussing this publication.

• Integrated Circuits and Semiconductor Failure Analysis
• Ovarian cancer diagnosis and treatment
• PARP inhibition in cancer therapy